Table 1.
Clinicopathological variables among patients with cLN(-) MCC by primary anatomic site
| HN (n=42) | NHN (n=38) | ||||
|---|---|---|---|---|---|
|
| |||||
| n | % | n | % | p-value | |
|
| |||||
| Age at diagnosis, years, median [IQR] | 70 [66–77] | 66 [57–73] | 0.020 | ||
| Sex | |||||
| Male | 32 | 76% | 20 | 53% | 0.027 |
| Female | 10 | 24% | 18 | 47% | |
| Race/Ethnicity | 0.91 | ||||
| White | 38 | 91% | 33 | 86% | |
| Hispanic | 2 | 5% | 3 | 8% | |
| Black | 1 | 2% | 1 | 3% | |
| Asian | 1 | 2% | 1 | 3% | |
| Immunocompromised | 7 | 17% | 7 | 18% | 0.84 |
| Prior history of cancer | 28 | 67% | 25 | 66% | 0.93 |
| History of skin cancer | 23 | 55% | 17 | 45% | 0.37 |
|
| |||||
| Primary tumor features | |||||
| Mitoses/mm2, median, [IQR] | 29 [15–60] | 33 [19–52] | 0.72 | ||
| T-stage | 0.78 | ||||
| T1 | 31 | 74% | 27 | 71% | |
| T2+ | 11 | 26% | 11 | 29% | |
| Lymphovascular invasion | 16 | 38% | 19 | 50% | 0.24 |
| Nodal status | |||||
| Nodal evaluation by SLNB or LND | 26 | 62% | 38 | 100% | <0.001 |
| 1 node positive | 6 | 23% | 10 | 26% | 0.78 |
| 2–3 nodes positive | 4 | 15% | 5 | 13% | |
| >3 nodes positive | 1 | 4% | 0 | 0% | |